AstraZeneca Provides Update On SERENA-4 Phase III Trial Of Etcamah In Combination With Palbociclib In Upfront First-Line Advanced ER-Positive Breast Cancer

AstraZeneca's experimental breast cancer drug, camizestrant, failed a late-stage trial. Citi maintained a 'buy' rating and £178 target price, citing investor preparedness and the drug's potential in other uses. The stock showed minimal movement. Citi noted the failure reduces the drug's valuation by about 2.5% but is offset by positive outlooks for other trials and AstraZeneca's strong pipeline.

AstraZeneca reported eight-year results from the ADAURA trial, showing Tagrisso (osimertinib) reduced death risk by 47-48% vs. placebo in early-stage EGFRm NSCLC patients. 74-79% of Tagrisso patients were alive at eight years. Data was presented at the IASLC 2026 World Conference on Lung Cancer and published in the Journal of Thoracic Oncology. According to AstraZeneca, this reinforces Tagrisso as the standard of care.

AstraZeneca's SERENA-4 Phase III trial for Etcamah (camizestrant) with palbociclib in 1st-line advanced ER-positive breast cancer did not meet the primary endpoint of progression-free survival, though a numerical improvement was observed. The trial involved 1,371 patients. Etcamah is approved in the US, EU, and Japan for HR-positive, HER2-negative breast cancer with ESR1 mutation, based on SERENA-6 trial results.

AstraZeneca's cancer drug camizestrant missed the primary endpoint in the SERENA-4 trial for first-line breast cancer, though shares rose 3.4% to 12,106p. The drug showed numerical improvement in progression-free survival but lacked statistical significance. The company plans to focus on other trials and approved uses. The stock is within its 52-week range of 9,826.66p to 15,467.70p.

AstraZeneca's (AZN) TAGRISSO showed an 8-year survival benefit in early-stage EGFR-mutated lung cancer, reducing death risk by 47-48% in trials. 74-79% of treated patients survived, per ADAURA Phase III data. AZN stock rose 0.96% in pre-market trading.

AstraZeneca (AZN) reported positive Phase III trial results for Enhertu, its lung cancer treatment, showing a 37% reduction in disease progression risk. The company offers a 2.0% dividend yield with a 47% payout ratio and is undervalued by 11.6% according to GF Value. AZN's GF Score is 77, reflecting strong profitability and valuation. Insiders have sold $2.2M in shares, while 15 gurus hold positions, with mixed recent activity. AZN has a market cap of $245.28B and operates in the healthcare sec